Remove Atherosclerosis Remove Biomarkers Remove Circulation
article thumbnail

Identification of microRNA biomarkers simultaneously expressed in circulating extracellular vesicles and atherosclerotic plaques

Frontiers in Cardiovascular Medicine

The early detection of plaques by circulating biomarkers is highly clinically relevant to prevent the occurrence of major complications such as stroke or heart attacks. BackgroundAtherosclerosis is a widespread disorder of the cardiovascular system. EVs were isolated from serum by precipitation.

Plaque 52
article thumbnail

Associations between circulating proteins and cardiometabolic diseases: a systematic review and meta-analysis of observational and Mendelian randomisation studies

Heart BMJ

Background Integration of large proteomics and genetic data in population-based studies can provide insights into discovery of novel biomarkers and potential therapeutic targets for cardiometabolic diseases (CMD). We aimed to synthesise existing evidence on the observational and genetic associations between circulating proteins and CMD.

article thumbnail

American Heart Month Puts Spotlight on Cardiovascular Disease and Stroke Statistics

DAIC

February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country embark on American Heart Month, DAIC has compiled a snapshot of significant cardiovascular disease (CVD) and stroke statistics, along with a review of the atherosclerosis drug market. percent Compound Annual Growth Rate (CAGR).

article thumbnail

The impact of inflammatory and oxidative stress biomarkers on the sympathetic nervous system in severe coronary atherosclerosis

Frontiers in Cardiovascular Medicine

Systemic activation of the SNS was estimated through circulating levels of norepinephrine (NE). Elevated levels of circulating pro-inflammatory markers were significantly correlated with increased NE concentrations (for IL-1β: p < 0.001, r = 0.49; for IL-6 and NE: p = 0.003, r = 0.32; for HIF-1α and NE: p = 0.049, r = 0.21).

article thumbnail

Roche's Lp(a) Gen.2 Molarity Assay Receives FDA Clearance

DAIC

This clearance comes in advance of disease-modifying therapies on the horizon expected to help clinicians use this biomarker to guide patients to improved cardiovascular health, saidBrad Moore, president and CEO at Roche Diagnostics North America. Circulation. The development of the Tina-quant Lipoprotein (a) Gen.2 Arnett DK et al.

article thumbnail

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

DAIC

1,6 Until recently atherosclerosis has been thought of as the result of passive lipid accumulation in the vessel wall. However, the development of atherosclerosis is now known to be much more complex, with a key role for immune cells and inflammation in conjunction with hyperlipidemia and elevated LDL levels.7

article thumbnail

Abstract 4136687: VTRNA2-1 Promoter Methylation as a Prognostic Biomarker in Peripheral Artery Disease: Implications for Maternal Nutritional Influence

Circulation

Circulation, Volume 150, Issue Suppl_1 , Page A4136687-A4136687, November 12, 2024. Background:Peripheral artery disease (PAD) is associated with high morbidity and mortality and is closely related to diabetes mellitus (DM) and atherosclerosis. 6.97, p=0.024), amputations (HR 2.58, 95% CI 1.02-6.57,